Stockreport

Forty Seven, Inc. Granted Fast Track Designation for Magrolimab (5F9) for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia

FORTY SEVEN  (FTSV) 
Last forty seven earnings: 11/12 07:01 am Check Earnings Report
PDF MENLO PARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macroph [Read more]